Connor Iapoce

In the inaugural episode of "New Insight with Veeral Sheth, MD," Dr. Sheth speaks with Arshad Khanani, MD on exciting developments from 2022, and a look at both the conference and treatment landscape unfolding in 2023.

An analysis of the HIT study suggested eyes with AMD treated with hydroxychloroquine experienced less growth and less drusen formation than those treated with control at two-year follow-up.

At 1-year follow-up, intravitreal aflibercept and brolucizumab reportedly improved vision in treatment-naïve patients with submacular hemorrhage secondary to AMD, unless vitreous hemorrhage developed.

Retrospective analyses suggest the feasibility of using FAF images, OCT volumes to predict GA growth rates and area using a multitask deep learning approach.

In the case of another situation similar to COVID-19 home confinement, the majority of the patients with nAMD in a Swiss study would prefer a visit to the clinic over telemedicine to monitor their disease.

Compared with individuals with normal glycemic status, a recent analysis found AMD risk increased with higher glycemic status and longer duration of diabetes.

Announced today by Horizon Therapeutics, the positive and statistically significant data supports the efficacy of teprotumumab across a spectrum of patients with TED regardless of disease activity or duration.

A new analysis of OCT biomarkers may help elucidate the utility of OCT biomarkers as therapeutic predictors of ranibizumab treatment among eyes with diabetic macular edema.

An analysis of 3 nationally representative data sets found that SDOH across domains of economic stability, educational attainment, health care access and quality, neighborhood and built environment, and social context were significant predictors of poor vision.

The Gold Standard Pathway Study noted statistically significant reductions in mean IOP and mean medication count from baseline was observed in both treatment arms at all visits.

The ESSENCE-2 study reported superiority of the water-free cyclosporine ophthalmic solution to vehicle in tCFS score at day 29, confirming results from ESSENCE-1.

After a two-year intensive therapy period, visual acuity was maintained or improved in nearly half of the ranibizumab-treated group and more than half of the aflibercept-treated group, but severely declined during the post-intensive period.

Our highlights from March 2023 included a teaser episode of a new KOL-led podcast, a feature elucidating a rare eye disease, and a look at the development of new therapies for geographic atrophy.

A recent analysis suggests cardiovascular and socioeconomic factors explain one‐quarter of the racial and ethnic differences in arterial stiffness of youth with type 1 diabetes.

In families carrying very rare AMD-causing variants, the analysis found two proteins that may be the driving force behind AMD pathology in affected patients.

A systematic review and meta-analysis found the prevalence of diabetes increases with COVID-19 severity, with diabetes accounting for 9.5% of severe COVID-19 cases and 16.8% of deaths.

The presence of IRF at baseline harmed treatment response, while other factors were negligible on how well patients with nAMD responded to a loading dose of aflibercept.

The reduced dosing of azithromycin supports its use as an alternative to doxycycline for at least 6 weeks in patients with moderate to severe meibomian gland dysfunction.

Our March 2023 cardiology month in review features top headlines from ACC.23, an approval for children with HoFH, and a feature celebrating the 10-year anniversary of the first SGLT2 inhibitor approval.

New trial results suggest the overall DONFL score was similar between a temporal inverted ILM flap technique and conventional ILM peeling in macular hole surgery.

A systematic review and meta-analysis suggested the relative risk per Gy increased for all cardiovascular disease and for the four major subtypes of cardiovascular disease.

Our latest podcast offering is an in-depth dive into ophthalmology hosted by Dr. Sheth, featuring conversations with experts on the latest research, conference news, and daily practice.

Three-year results from the CIRTED trial reported no clear evidence of benefit for the addition of azathioprine to high dose oral steroid in individuals with moderate to severe TED.

An entire population gradually loses their vision, impeding everyday activities like driving in the dark, while investigators explore gene therapies in a race against the clock.

OCT features including a thin double-layer sign and cRORA in the fellow eye were associated with an increased risk of progression to cRORA over 2 years in eyes with iAMD.

Children exposed to maternal COVID-19 during pregnancy showed lower birth weight, lower birth BMI, and accelerated postnatal weight gain, compared with those unexposed.

This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.

Smokers with TED showed less improvement in diplopia, proptosis, and overall clinical activity score compared to non-smokers.

A new cohort study suggested the number of days per week taking 8000 steps or more was associated with a decreased risk of all-cause and cardiovascular mortality.

The expert consensus statement provides updated recommendations on evidence-based best practices for transcatheter LAAC, with a focus on endovascular devices.